PRO-C3-Levels in patients with HIV/HCV-Co-Infection reflect fibrosis stage and degree of portal hypertension

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Jansen, Christian ^a   Leeming, Diana J ^b   Mandorfer, Mattias ^c   Byrjalsen, Inger ^b   Schierwagen, Robert ^a   Schwabl, Philipp ^c   Karsdal, Morten A ^b   Anadol, Evrim ^a   Strassburg, Christian P ^a   Rockstroh, Jürgen ^a,d   Peck Radosavljevic, Markus ^c   Møller, Søren ^e   Bendtsen, Flemming ^e   Krag, Aleksander ^f   Reiberger, Thomas ^c   Trebicka, Jonel ^a  

^a UNIVERSITY OF BONN   (Germany)

^b NORDIC BIOSCIENCE A S   (Denmark)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; DEGRADED N TERMINAL PROPEPTIDE OF TYPE III COLLAGEN; DEGRADED TYPE IV COLLAGEN; DEGRADED TYPE V COLLAGEN; GELATINASE A; GELATINASE B; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5;

ADULT; ARTICLE; BLOOD LEVEL; FEMALE; FIB4 SCORE; HEPATIC VENOUS PRESSURE GRADIENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PORTAL HYPERTENSION; SCORING SYSTEM; VENOUS PRESSURE; BLOOD; CHRONIC HEPATITIS C; EXTRACELLULAR MATRIX; IMMUNOLOGY; INJURIES; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PORTAL VEIN BLOOD PRESSURE; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; COINFECTION; COMPLEMENT C3; COMPLEMENT C4; COMPLEMENT C5; EXTRACELLULAR MATRIX; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PORTAL PRESSURE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84907482267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108544     Document Type: Article

References (44)

1. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL (2001) Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 285: 1308-1315.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29.
3. Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, et al. (2005) Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 19: 2117-2125.
4. Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, et al. (2007) Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 14: 183-188.
5. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K (2011) Increasing burden of liver disease in patients with HIV infection. Lancet 377: 1198-1209.
6. Deng A, Chen C, Ishizaka Y, Chen X, Sun B, et al. (2014) Human immunodeficiency virus type 1 Vpr increases hepatitis C virus RNA replication in cell culture. Virus Res 184C: 93-102.
7. Vali B, Jones RB, Sakhdari A, Sheth PM, Clayton K, et al. (2010) HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 40: 2493-2505.
8. Bowen DG, Walker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946-952.
9. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, et al. (1999) Analysis of a successful immune response against hepatitis C virus. Immunity 10: 439-449.
10. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, et al. (1999) Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117: 933-941.
11. Rotman Y, Liang TJ (2009) Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 83: 7366-7374.
12. Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, et al. (2005) HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 41: 779-789.
13. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC (2009) The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 6: 573-582.
14. Tsochatzis EA, Bosch J, Burroughs AK (2014) Liver cirrhosis. Lancet.
15. Garcia-Pagan JC, Di Pascoli M, Caca K, Laleman W, Bureau C, et al. (2013) Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 58: 45-50.
16. Garcia-Pagan JC, Reverter E, Abraldes JG, Bosch J (2012) Acute variceal bleeding. Semin Respir Crit Care Med 33: 46-54.
17. Leeming DJ, Karsdal MA, Byrjalsen I, Bendtsen F, Trebicka J, et al. (2013) Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther 38: 1086-1096.
18. Schierwagen R, Leeming DJ, Klein S, Granzow M, Nielsen MJ, et al. (2013) Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. Front Physiol 4: 195.
19. Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, et al. (2011) A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 16: 616-628.
20. Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, et al. (2013) Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 11: 70-92.
21. Larrousse M, Laguno M, Segarra M, De Lazzari E, Martinez E, et al. (2007) Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 46: 304-311.
22. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, et al. (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115: 2223-2233.
23. Reiberger T, Payer BA, Ferlitsch A, Sieghart W, Breitenecker F, et al. (2012) A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. Antivir Ther 17: 1327-1334.
24. Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, et al. (2011) Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 9: 602-608 e601.
25. Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, et al. (2013) Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 62: 1634-1641.
26. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Schwabl P, et al. (2012) Noninvasive screening for liver fibrosis and portal hypertension by transient elastography-a large single center experience. Wien Klin Wochenschr 124: 395-402.
27. Schwabl P, Bota S, Salzl P, Mandorfer M, Payer B, et al. (2014) New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Int.
28. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, et al. (2007) FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46: 32-36.
29. Nielsen MJ, Nedergaard AF, Sun S, Veidal SS, Larsen L, et al. (2013) The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 5: 303-315.
30. Veidal SS, Karsdal MA, Nawrocki A, Larsen MR, Dai Y, et al. (2011) Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair 4: 22.
31. Veidal SS, Larsen DV, Chen X, Sun S, Zheng Q, et al. (2012) MMP mediated type V collagen degradation (C5M) is elevated in ankylosing spondylitis. Clin Biochem 45: 541-546.
32. Liedtke C, Luedde T, Sauerbruch T, Scholten D, Streetz K, et al. (2013) Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair 6: 19.
33. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, et al. (2013) Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 58: 234-239.
34. Buck M, Garcia-Tsao G, Groszmann RJ, Stalling C, Grace ND, et al. (2014) Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology 59: 1052-1059.
35. Bosch J, Garcia-Tsao G (2009) Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: and the winner is. Hepatology 50: 674-677.
36. Bosch J (2000) Prevention of variceal rebleeding: endoscopes, drugs, and more. Hepatology 32: 660-662.
37. Mandorfer M, Payer BA, Schwabl P, Steiner S, Ferlitsch A, et al. (2014) Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver Int.
38. Alesiani M, Pellegrini Giampietro DE, Cherici G, Galli A, Moroni F (1990) The guinea pig myenteric plexus as a tool to characterize drugs active at the glycine recognition site of the NMDA receptors. Pharmacol Res 22 Suppl 1: 15-16.
39. Estes JD (2013) Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues. Immunol Rev 254: 65-77.
40. Leeming DJ, Sand JM, Nielsen MJ, Genovese F, Martinez FJ, et al. (2012) Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Biomark Insights 7: 119-126.
41. Sanchez-Conde M, Miralles P, Bellon JM, Rincon D, Ramirez M, et al. (2011) Use of transient elastography (FibroScan(R)) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients. J Viral Hepat 18: 685-691.
42. Liu W, Zheng J, Xing R (2014) Clinical significance of a scoring formula of liver injury for the preoperative evaluation of patients with liver cirrhosis. Eur J Gastroenterol Hepatol 26: 95-100.
43. van Beek JH, de Moor MH, de Geus EJ, Lubke GH, Vink JM, et al. (2013) The genetic architecture of liver enzyme levels: GGT, ALT and AST. Behav Genet 43: 329-339.
44. M'Kada H, Munteanu M, Perazzo H, Ngo Y, Ramanujam N, et al. (2011) What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). Regul Toxicol Pharmacol 60: 290-295.